Skip to content

Monte Rosa Therapeutics, Inc. GLUE Prepaid & Other Current

Prepaid & Other Current at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$13.66M-2.6%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$26.5M+48.9%
Immunome logo
ImmunomeIMNM
$11.62M+100%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$11.43M+58.2%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$13.95M+29.2%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$20.44M+81.2%

Other financials

Income statement

See full
Revenue$4.2M-95.0%
Operating income-$50.0M-214%
Net income-$44.5M-195%
EPS (diluted)-$0.45-179%

Balance sheet

See full
Cash & equivalents$159.9M+104%
Total debt$39.1M-6.7%
Total equity$521.9M+89.7%
Total assets$736.4M+87.3%

Cash flow

See full
Operating cash flow-$37.4M+17.9%
CapEx$1.9M+17.7%
Free cash flow-$39.2M+16.7%

Valuation

See full
Market cap$1.75B+361%
Enterprise value$1.63B+381%
P/S40.7×+38.4×

Profitability

See full
Operating margin-345.2%
Net margin-302.6%
FCF margin-45.8%-64.9pp

Returns & leverage

See full
Return on equity-32.6%
Debt / equity0.1×-0.1×
Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s prepaid & other current?
Monte Rosa Therapeutics, Inc. (GLUE) reported prepaid & other current of $6.72M in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s prepaid & other current changed year-over-year?
Monte Rosa Therapeutics, Inc.'s prepaid & other current increased by 40.0% year-over-year, from $4.8M to $6.72M.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s prepaid & other current?
Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s prepaid & other current has grown at a 25.2% compound annual growth rate (CAGR), from $8.69M to $21.37M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.